May 14, 2019 / 05:00PM GMT
Ying Huang - BofA Merrill Lynch, Research Division - Director in Equity Research
(technical difficulty)
at Bank of America Merrill Lynch. Actually, before I start the next session, I almost forgot in the last few sessions to do some commercial. That is it's the season for II survey, Institutional Investor survey. This year, they changed the protocol, so would very much appreciate it if you can vote for BofA Merrill Lynch as a firm. And I think the firm definitely deserve a 5-star rating. And at the same time, if you can vote for our team in the large cap biotech category, that will be much appreciated.
So with that, we're going to have the next company, which is Gilead Sciences. I don't think Gilead needs any introduction. It's a household name in my sector, biotech. And we're very pleased to have Robin Washington, the Chief Financial Officer of Gilead; and also Dr. John McHutchison, Head of R&D from Gilead, representing the company. So with that, I'm going to invite both Robin and John to the stage. We're going to do the fireside chat here.
Gilead Sciences Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 14, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers